Your browser doesn't support javascript.
loading
Inflammatory Proteins HMGA2 and PRTN3 as Drivers of Vulvar Squamous Cell Carcinoma Progression.
Fatalska, Agnieszka; Rusetska, Natalia; Bakula-Zalewska, Elwira; Kowalik, Artur; Zieba, Sebastian; Wroblewska, Agnieszka; Zalewski, Kamil; Goryca, Krzysztof; Domanski, Dominik; Kowalewska, Magdalena.
Afiliación
  • Fatalska A; Mass Spectrometry Laboratory, Institute of Biochemistry and Biophysics-Polish Academy of Sciences, 02-106 Warsaw, Poland.
  • Rusetska N; Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Bakula-Zalewska E; Department of Pathology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Kowalik A; Department of Molecular Diagnostics, Holycross Cancer Center, 25-734 Kielce, Poland.
  • Zieba S; Division of Medical Biology, Institute of Biology, Jan Kochanowski University, 25-369 Kielce, Poland.
  • Wroblewska A; Department of Molecular Diagnostics, Holycross Cancer Center, 25-734 Kielce, Poland.
  • Zalewski K; Department of Gynecology, Holy Family Hospital, 02-544 Warsaw, Poland.
  • Goryca K; Department of Molecular and Translational Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland.
  • Domanski D; Department of Gynecologic Oncology, Holycross Cancer Center, 25-734 Kielce, Poland.
  • Kowalewska M; Chair and Department of Obstetrics, Gynecology and Oncology, 2nd Faculty of Medicine, Warsaw Medical University, 03-242 Warsaw, Poland.
Cancers (Basel) ; 13(1)2020 Dec 23.
Article en En | MEDLINE | ID: mdl-33374674
ABSTRACT
Current knowledge on the biology of squamous cell vulvar carcinoma (VSCC) is limited. We aimed to identify protein markers of VSCC tumors that would permit to stratify patients by progression risk. Early-stage tumors from patients who progressed (progVSCC) and from those who were disease-free (d-fVSCC) during follow-up, along with normal vulvar tissues were examined by mass spectrometry-based proteomics. Differentially expressed proteins (DEPs) were then verified in solid tissues and blood samples of patients with VSCC tumors and vulvar premalignant lesions. In progVSCC vs. d-fVSCC tumors, the immune response was the most over-represented Gene Ontology category for the identified DEPs. Pathway profiling suggested bacterial infections to be linked to aggressive VSCC phenotypes. High Mobility Group AT-Hook 2 (HMGA2) and Proteinase 3 (PRTN3) were revealed as proteins predicting VSCC progression. HMGA2 and PRTN3 abundances are associated with an aggressive phenotype, and hold promise as markers for VSCC patient stratification. It appears that vulvovaginal microflora disturbances trigger an inflammatory response contributing to cancer progression, suggesting that bacterial rather than viral infection status should be considered in the development of targeted therapies in VSCC.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Polonia

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: Polonia